StockNews.com Initiates Coverage on Trinity Biotech (NASDAQ:TRIB)

Stock analysts at StockNews.com started coverage on shares of Trinity Biotech (NASDAQ:TRIB) in a report issued on Tuesday. The firm set a “buy” rating on the stock.

Trinity Biotech Stock Up 2.7 %

TRIB opened at $1.91 on Tuesday. The stock has a market cap of $14.55 million, a PE ratio of -0.60 and a beta of 1.21. Trinity Biotech has a 52 week low of $1.81 and a 52 week high of $6.20. The business’s fifty day simple moving average is $2.16 and its 200 day simple moving average is $2.31.

Trinity Biotech (NASDAQ:TRIB) last released its earnings results on Wednesday, January 31st. The company reported ($0.90) EPS for the quarter. The company had revenue of $14.68 million during the quarter. As a group, equities analysts anticipate that Trinity Biotech will post -1.5 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Atria Wealth Solutions Inc. grew its stake in shares of Trinity Biotech by 38.9% during the fourth quarter. Atria Wealth Solutions Inc. now owns 34,300 shares of the company’s stock valued at $34,000 after buying an additional 9,600 shares during the last quarter. Renaissance Technologies LLC grew its stake in shares of Trinity Biotech by 2.4% during the second quarter. Renaissance Technologies LLC now owns 1,503,336 shares of the company’s stock valued at $1,842,000 after buying an additional 34,900 shares during the last quarter. Virtu Financial LLC bought a new position in shares of Trinity Biotech during the first quarter valued at about $40,000. Finally, Whitefort Capital Management LP grew its stake in shares of Trinity Biotech by 1,067.8% during the first quarter. Whitefort Capital Management LP now owns 409,517 shares of the company’s stock valued at $434,000 after buying an additional 374,449 shares during the last quarter. Institutional investors own 78.97% of the company’s stock.

About Trinity Biotech

Trinity Biotech plc acquires, together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.